drugset
drugset / Trial / NCT05544916

A Study to Evaluate the Safety and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections

NCT05544916 ↗

Phase 3 Completed 260 enrolled Valenta Pharm JSC
RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of the study was to evaluate the effectiveness of XC221, tablets, at a dose of 200 mg/day compared to placebo in patients with uncomplicated influenza or other acute respiratory viral infections (ARIs). An additional purpose of the study was to evaluate the safety of XC221, tablets, at a dose of 200 mg/day compared to placebo in patients with uncomplicated influenza or other ARIs.

Timeline

Start
2022-08-05
Primary completion
2023-02-01
Completion
2023-05-04

Drugs

EvaluationDrugModalityDoseRoute
Subject XC221 Unknown 100 mg —

Indications

influenza